source
- Novartis signs up to $3.2 billion deal with Korea's Alteogen for subcutaneous drug delivery technologyNovartis has entered an option and license agreement with Korean biotech Alteogen to use its ALT-B4 subcutaneous delivery platform, a partnership that could be worth up to $3.2 billion if all optio…
- Novartis CAR-T trial deaths spark safety concerns for autoimmune applicationsNovartis disclosed that three participants in its CAR-T cell therapy trials for autoimmune disease have died. The company said the deaths were reported to health authorities and are under investiga…